Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The company will donate 5000 nebulizers to primary health care centres in rural India
The company is focused on the development of novel treatments for RNA viruses
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
An MoU was signed between B Medical Systems and Gujarat government recently
Subscribe To Our Newsletter & Stay Updated
